Kidney Health Australia is the peak body for kidney disease in Australia, and the patient voice on kidney related issues. For the latest information on kidney disease statistics, treatments or research, or to find out about other kidney conditions, please contact us.
We can also reach out to our kidney community to put forward the patient perspective on issues related to kidney disease.
For media enquiries, you can speak to our Kidney Media team on 0434 801 485, 0420 531 167 or email kidneymedia@kidney.org.au.
"I would like to acknowledge the research grant awarded by Kidney Health Australia which has provided critical support to our research in kidney diseases. Our project funded by Kidney Health Australia research grant (KHA2021XMC) aimed to define the role of stem cell produced exosomes in mitigating or preventing the progression of chronic kidney disease in mouse models. A part of the results raised from this project has significantly contributed to a great successful NHMRC Investigator Grant led by Professor Carol Pollock who is my supervisor. This successful NHMRC grant ($2m) has secured our research in CKD for next 5 years through supporting both staff employment and supplies of consumables. So, this Kidney Health Australia research grant has been very important to our future research in CKD, many thanks!" - Xin-Ming, Sydney Medical School
Kidney decline can happen quickly. Like many Australians, Lesley didn't experience a slow deterioration into kidney failure.
She instead lost about 90 per cent of her kidney function before anyone — including her doctors — knew anything was wrong.
Because the body compensates for that loss of function, it's common for people to experience very few or no symptoms at all until they have permanent damage.
We warmly welcome the announcement about the listing of oral therapy dapagliflozin on the Pharmaceutical Benefits Scheme (PBS) in Australia from 1 September 2022 to reduce the risk of progressive decline in kidney function in adults with proteinuric chronic kidney disease who meet the specific criteria of the PBS listing. This is the first new treatment added to the PBS in more than 20 years for Australians living with proteinuric chronic kidney disease, and will impact so many Australians and members of our kidney family.
This medicine has previously been used to manage type 2 diabetes and heart failure with reduced ejection fraction, and it is pleasing to see that it will now be available as an accessible option supporting the treatment of patients diagnosed with proteinuric chronic kidney disease.
The latest report from the Australian Institute of Health and Welfare (AIHW), Chronic kidney disease: Australian facts shows the number of Australians receiving kidney replacement therapy more than doubled between 2000 and 2020, from 11,700 to 27,700. The report highlights that kidney disease remains a significant health issue, particularly among Aboriginal and Torres Strait Islander people.
New data analysis by the Australian Institute of Health and Welfare has shown the devastating effects of living with two or more chronic conditions, prompting renewed calls by health groups for Government commitment to tackle chronic disease.
The Big Red Kidney Bus is back on the road, but this time with a different job – giving vulnerable and at-risk communities an opportunity to have the COVID-19 vaccine. Read the attached media release from NSW Health to find out more.
